HIV/AIDS Tuberculosis
Rifampicin does not affect enfuvirtide pharmacokinetics
Published in TB and Outbreaks Week, January 20th, 2004
Scientists in Thailand sought "to determine whether rifampicin influences the pharmacokinetics of enfuvirtide in HIV-1-infected patients."
"In a single-center, open-label, one-sequence crossover, clinical pharmacology study, 12 HIV-1-infected adults received enfuvirtide (90 mg, twice daily) on days one to three and days 11 to 13 (morning dose only on days three and 13) and rifampicin (600 mg, once daily) from days four to 13," explained M.A. Boyd and coauthors working with the HIV Netherlands Australia Thailand Research...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
More Articles from TB and Outbreaks Week
- Outbreaks
Enrichment culture could aid laboratory detection of C. perfringens - Antibiotic Research
Study of E. coli given cecropin B reveals antibiotic's mode of action - Antimicrobials
Lentivirus lytic peptide derivatives selectively toxic to airway pathogens - Breastfeeding
Continuing to nurse while dealing with viral infection is okay - CNS Disease
Extracellular phospholipase A2 inhibitors can inhibit inflammation in CNS - Chlamydia
Delay in cell death may lower Chlamydia infection but increase pathology - More from this issue of TB and Outbreaks Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
